Estudo randomizado | Intervenção com metotrexato em pacientes com artralgia sob risco de artrite reumatoide para reduzir o desenvolvimento da artrite persistente e o impacto da doença.

Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial – The Lancet (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Treatment before patients develop rheumatism provides lasting relief – Leiden University Medical Centre

Comentários no Twitter:

NEW in @TheLancet—The TREAT EARLIER trial shows that initiated in patients with arthralgia at risk of #rheumatoidarthritis did not prevent the development of clinical arthritis, but did modify the disease course https://t.co/5zh7lqb4NJ pic.twitter.com/lJflW9Prwm

— The Lancet Rheumatology (@TheLancetRheum) July 22, 2022

🆕🔥Methotrexate,🇳🇱study
MTX in pre-arthritis stage➡️ did not prevent the development of clinical arthritis
but ➡️sustained improvement in
♦️MRI-detected inflammation,
♦️Symptoms (Pain & EMS)
♦️Related impairments (HAQ n Presentism)
Vs placebohttps://t.co/I0IdKydPME pic.twitter.com/cNi6AhO151

— EnvisionRheumat (@ERheumat) July 29, 2022